Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by West Oak Capital LLC

West Oak Capital LLC boosted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3,695.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,277 shares of the medical equipment provider’s stock after buying an additional 2,217 shares during the quarter. West Oak Capital LLC’s holdings in Intuitive Surgical were worth $1,189,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ISRG. State Street Corp increased its position in shares of Intuitive Surgical by 1.4% in the 3rd quarter. State Street Corp now owns 15,050,121 shares of the medical equipment provider’s stock worth $7,393,673,000 after purchasing an additional 210,363 shares during the last quarter. FMR LLC increased its holdings in Intuitive Surgical by 8.3% in the third quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock valued at $5,389,765,000 after buying an additional 838,793 shares during the last quarter. Geode Capital Management LLC raised its stake in Intuitive Surgical by 1.9% during the third quarter. Geode Capital Management LLC now owns 7,512,925 shares of the medical equipment provider’s stock valued at $3,677,194,000 after buying an additional 143,440 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in Intuitive Surgical by 1.8% during the 3rd quarter. Fisher Asset Management LLC now owns 4,782,381 shares of the medical equipment provider’s stock worth $2,349,441,000 after buying an additional 86,208 shares during the last quarter. Finally, Baillie Gifford & Co. grew its position in shares of Intuitive Surgical by 0.6% in the 3rd quarter. Baillie Gifford & Co. now owns 3,848,547 shares of the medical equipment provider’s stock worth $1,890,676,000 after acquiring an additional 24,183 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Intuitive Surgical news, CFO Jamie Samath sold 108 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total transaction of $58,542.48. Following the completion of the sale, the chief financial officer now directly owns 8,757 shares of the company’s stock, valued at approximately $4,746,819.42. This represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mark Brosius sold 2,128 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total transaction of $1,095,920.00. Following the completion of the transaction, the senior vice president now directly owns 273 shares in the company, valued at approximately $140,595. This trade represents a 88.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,190 shares of company stock worth $25,012,927. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Trading Up 0.6 %

NASDAQ:ISRG traded up $3.45 during midday trading on Friday, hitting $547.47. 1,732,123 shares of the stock were exchanged, compared to its average volume of 1,344,848. The company has a market capitalization of $195.00 billion, a price-to-earnings ratio of 88.02, a P/E/G ratio of 5.31 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $355.17 and a one year high of $556.23. The business has a 50-day moving average price of $535.11 and a two-hundred day moving average price of $493.61.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.32. The business had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. Sell-side analysts forecast that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ISRG has been the topic of several research reports. Truist Financial upped their price target on Intuitive Surgical from $570.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler restated an “overweight” rating and issued a $538.00 price target (up from $495.00) on shares of Intuitive Surgical in a research report on Friday, October 18th. BTIG Research lifted their price target on shares of Intuitive Surgical from $535.00 to $561.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Leerink Partners increased their price objective on shares of Intuitive Surgical from $489.00 to $502.00 in a research note on Thursday, October 17th. Finally, Royal Bank of Canada lifted their target price on Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a research note on Friday, October 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $554.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.